CN103819564A - 用于将gdnf和bdnf递送至中枢神经系统的融合蛋白 - Google Patents
用于将gdnf和bdnf递送至中枢神经系统的融合蛋白 Download PDFInfo
- Publication number
- CN103819564A CN103819564A CN201410030902.XA CN201410030902A CN103819564A CN 103819564 A CN103819564 A CN 103819564A CN 201410030902 A CN201410030902 A CN 201410030902A CN 103819564 A CN103819564 A CN 103819564A
- Authority
- CN
- China
- Prior art keywords
- disease
- angiopep
- seq
- polypeptide
- xaa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 title claims abstract description 100
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 title abstract description 96
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 title abstract description 56
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 title abstract description 56
- 108020001507 fusion proteins Proteins 0.000 title abstract description 5
- 102000037865 fusion proteins Human genes 0.000 title abstract description 5
- 210000003169 central nervous system Anatomy 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 76
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 56
- 108010064942 Angiopep-2 Proteins 0.000 claims abstract description 51
- 201000010099 disease Diseases 0.000 claims abstract description 49
- 239000012634 fragment Substances 0.000 claims abstract description 33
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 13
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 12
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract description 11
- 210000001218 blood-brain barrier Anatomy 0.000 claims abstract description 8
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 242
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 160
- 229920001184 polypeptide Polymers 0.000 claims description 156
- 235000001014 amino acid Nutrition 0.000 claims description 79
- 150000001413 amino acids Chemical class 0.000 claims description 76
- 238000000034 method Methods 0.000 claims description 30
- 102100033295 Glial cell line-derived neurotrophic factor Human genes 0.000 claims description 28
- 101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 206010003591 Ataxia Diseases 0.000 claims description 9
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000002441 reversible effect Effects 0.000 claims description 8
- 208000006011 Stroke Diseases 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 208000031277 Amaurotic familial idiocy Diseases 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 6
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 claims description 6
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 claims description 6
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 claims description 6
- 206010003594 Ataxia telangiectasia Diseases 0.000 claims description 5
- 208000022526 Canavan disease Diseases 0.000 claims description 5
- 201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 claims description 5
- 206010049020 Encephalitis periaxialis diffusa Diseases 0.000 claims description 5
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 5
- 208000027747 Kennedy disease Diseases 0.000 claims description 5
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 5
- 208000005587 Refsum Disease Diseases 0.000 claims description 5
- 208000021235 Schilder disease Diseases 0.000 claims description 5
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims description 5
- 208000030597 adult Refsum disease Diseases 0.000 claims description 5
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 5
- 230000003961 neuronal insult Effects 0.000 claims description 5
- 210000000278 spinal cord Anatomy 0.000 claims description 5
- 208000011403 Alexander disease Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims description 4
- 208000010200 Cockayne syndrome Diseases 0.000 claims description 4
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims description 4
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 4
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims description 4
- 208000028226 Krabbe disease Diseases 0.000 claims description 4
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 4
- 201000002832 Lewy body dementia Diseases 0.000 claims description 4
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 4
- 102100026784 Myelin proteolipid protein Human genes 0.000 claims description 4
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 claims description 4
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims description 4
- 208000021811 Sandhoff disease Diseases 0.000 claims description 4
- 208000020339 Spinal injury Diseases 0.000 claims description 4
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims description 4
- 201000010901 lateral sclerosis Diseases 0.000 claims description 4
- 208000005264 motor neuron disease Diseases 0.000 claims description 4
- 208000001914 Fragile X syndrome Diseases 0.000 claims description 3
- 208000036626 Mental retardation Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 201000000585 muscular atrophy Diseases 0.000 claims description 3
- 208000024732 dysthymic disease Diseases 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 102000024452 GDNF Human genes 0.000 claims 4
- 239000000969 carrier Substances 0.000 claims 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 abstract description 55
- 230000006576 neuronal survival Effects 0.000 abstract description 4
- 201000000980 schizophrenia Diseases 0.000 abstract description 3
- 230000007514 neuronal growth Effects 0.000 abstract description 2
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 230000008499 blood brain barrier function Effects 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 description 77
- -1 Leu Chemical compound 0.000 description 21
- 239000003153 chemical reaction reagent Substances 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 18
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 17
- 125000000539 amino acid group Chemical group 0.000 description 16
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 13
- 230000004927 fusion Effects 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 11
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 11
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 9
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 9
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 125000003368 amide group Chemical group 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 7
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- 239000002773 nucleotide Chemical group 0.000 description 7
- 230000010412 perfusion Effects 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 150000008574 D-amino acids Chemical class 0.000 description 6
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 6
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 239000000710 homodimer Substances 0.000 description 5
- 125000001841 imino group Chemical group [H]N=* 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 150000003141 primary amines Chemical class 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 108010039627 Aprotinin Proteins 0.000 description 4
- 150000008575 L-amino acids Chemical class 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 101710162629 Trypsin inhibitor Proteins 0.000 description 4
- 229940122618 Trypsin inhibitor Drugs 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 229940108519 trasylol Drugs 0.000 description 4
- 239000002753 trypsin inhibitor Substances 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 108010016626 Dipeptides Proteins 0.000 description 3
- 102000018389 Exopeptidases Human genes 0.000 description 3
- 108010091443 Exopeptidases Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000014461 Ataxins Human genes 0.000 description 2
- 108010078286 Ataxins Proteins 0.000 description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 description 2
- 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical group OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical group CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 239000006035 Tryptophane Substances 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 2
- 150000003948 formamides Chemical group 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- NKAAEMMYHLFEFN-UHFFFAOYSA-M monosodium tartrate Chemical compound [Na+].OC(=O)C(O)C(O)C([O-])=O NKAAEMMYHLFEFN-UHFFFAOYSA-M 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000016273 neuron death Effects 0.000 description 2
- 208000002040 neurosyphilis Diseases 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 108010040003 polyglutamine Proteins 0.000 description 2
- 229920000155 polyglutamine Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 210000000449 purkinje cell Anatomy 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 208000002025 tabes dorsalis Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000031998 transcytosis Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 1
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 1
- GVJXGCIPWAVXJP-UHFFFAOYSA-N 2,5-dioxo-1-oxoniopyrrolidine-3-sulfonate Chemical compound ON1C(=O)CC(S(O)(=O)=O)C1=O GVJXGCIPWAVXJP-UHFFFAOYSA-N 0.000 description 1
- BLSAPDZWVFWUTL-UHFFFAOYSA-N 2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound OS(=O)(=O)C1CC(=O)NC1=O BLSAPDZWVFWUTL-UHFFFAOYSA-N 0.000 description 1
- DUAWRLXHCUAWMK-UHFFFAOYSA-N 2-iminiopropionate Chemical compound CC(=[NH2+])C([O-])=O DUAWRLXHCUAWMK-UHFFFAOYSA-N 0.000 description 1
- CXGYVVWOYNOMBX-UHFFFAOYSA-N 3-benzoylpyrrolidine-2,5-dione;pyrrole-2,5-dione Chemical compound O=C1NC(=O)C=C1.C=1C=CC=CC=1C(=O)C1CC(=O)NC1=O CXGYVVWOYNOMBX-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- DTRIDVOOPAQEEL-UHFFFAOYSA-N 4-sulfanylbutanoic acid Chemical compound OC(=O)CCCS DTRIDVOOPAQEEL-UHFFFAOYSA-N 0.000 description 1
- HCXJFMDOHDNDCC-UHFFFAOYSA-N 5-$l^{1}-oxidanyl-3,4-dihydropyrrol-2-one Chemical group O=C1CCC(=O)[N]1 HCXJFMDOHDNDCC-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000007333 Brain Concussion Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- IKAIKUBBJHFNBZ-LURJTMIESA-N Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CN IKAIKUBBJHFNBZ-LURJTMIESA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 101001043562 Homo sapiens Low-density lipoprotein receptor-related protein 2 Proteins 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-YGVKFDHGSA-N L-methionine S-oxide Chemical compound CS(=O)CC[C@H](N)C(O)=O QEFRNWWLZKMPFJ-YGVKFDHGSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100021922 Low-density lipoprotein receptor-related protein 2 Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- 125000000534 N(2)-L-lysino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C([H])([H])C(C([H])([H])N([H])[H])([H])[H] 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 101150056950 Ntrk2 gene Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
- 201000003629 Spinocerebellar ataxia type 8 Diseases 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000021235 carbamoylation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 238000011207 functional examination Methods 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 230000010005 growth-factor like effect Effects 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical class C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 125000003099 maleoyl group Chemical group C(\C=C/C(=O)*)(=O)* 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical class OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000012036 ultra high throughput screening Methods 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18624609P | 2009-06-11 | 2009-06-11 | |
| US61/186,246 | 2009-06-11 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010800317596A Division CN102459348A (zh) | 2009-06-11 | 2010-06-11 | 用于将gdnf和bdnf递送至中枢神经系统的融合蛋白 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103819564A true CN103819564A (zh) | 2014-05-28 |
Family
ID=43308346
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010800317596A Pending CN102459348A (zh) | 2009-06-11 | 2010-06-11 | 用于将gdnf和bdnf递送至中枢神经系统的融合蛋白 |
| CN201410030902.XA Pending CN103819564A (zh) | 2009-06-11 | 2010-06-11 | 用于将gdnf和bdnf递送至中枢神经系统的融合蛋白 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010800317596A Pending CN102459348A (zh) | 2009-06-11 | 2010-06-11 | 用于将gdnf和bdnf递送至中枢神经系统的融合蛋白 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20120196803A1 (enExample) |
| EP (1) | EP2440581A4 (enExample) |
| JP (1) | JP2012529272A (enExample) |
| CN (2) | CN102459348A (enExample) |
| AU (1) | AU2010258052A1 (enExample) |
| BR (1) | BRPI1012971A2 (enExample) |
| CA (1) | CA2764777A1 (enExample) |
| MX (1) | MX2011013258A (enExample) |
| WO (1) | WO2010142035A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107141354A (zh) * | 2017-05-05 | 2017-09-08 | 李斯文 | 一种融合蛋白及光敏剂复合物及其制备方法和应用 |
| CN114729324A (zh) * | 2019-07-24 | 2022-07-08 | 斯比根公司 | 永生化干细胞株的制备方法及其用途 |
| WO2025067354A1 (zh) * | 2023-09-28 | 2025-04-03 | 广州必贝特医药股份有限公司 | 抑制淀粉样前体蛋白(APP)基因表达的siRNA、药物及其应用 |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1583562E (pt) | 2003-01-06 | 2011-09-19 | Angiochem Inc | Angiopep-1, compostos relacionados, e suas utilizações |
| RU2422143C2 (ru) | 2005-07-15 | 2011-06-27 | Анджиокем Инк. | Усиление действия противораковых агентов |
| WO2008046228A1 (en) | 2006-10-19 | 2008-04-24 | Angiochem, Inc. | Compounds for stimulating p-glycoprotein function and uses thereof |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| CN102245642A (zh) | 2008-10-15 | 2011-11-16 | 安吉奥开米公司 | Glp-1激动剂的结合物及其用途 |
| BRPI0922689A2 (pt) | 2008-12-05 | 2018-11-06 | Angiochem Inc. | conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos |
| CN102300987A (zh) | 2008-12-17 | 2011-12-28 | 安吉奥开米公司 | 膜型-1基质金属蛋白抑制剂及其用途 |
| ES2729261T3 (es) | 2009-04-20 | 2019-10-31 | Angiochem Inc | Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2 |
| JP5932642B2 (ja) | 2009-07-02 | 2016-06-08 | アンジオケム インコーポレーテッド | 多量体ペプチドコンジュゲートおよびその使用 |
| WO2011153642A1 (en) * | 2010-06-10 | 2011-12-15 | Angiochem Inc. | Leptin and leptin analog conjugates and fusion proteins and uses thereof |
| EP2588490B1 (en) * | 2010-07-02 | 2017-02-22 | Angiochem Inc. | Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof |
| CA2881602A1 (en) | 2012-08-14 | 2014-02-20 | Angiochem Inc. | Peptide-dendrimer conjugates and uses thereof |
| JP6234331B2 (ja) * | 2014-06-13 | 2017-11-22 | 森永乳業株式会社 | 統合失調症治療剤 |
| CN107921143B (zh) | 2015-06-15 | 2021-11-19 | 安吉奥开米公司 | 用于治疗软脑膜癌病的方法 |
| KR20190008891A (ko) | 2016-05-13 | 2019-01-25 | 인스티튜토 데 메디시나 몰레큘라 | Ｉｌｃ３ 세포와 연관된 질환을 치료하는 방법 |
| WO2018089702A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Gdnf fusion polypeptides and methods of use thereof |
| US20240270855A1 (en) | 2021-06-03 | 2024-08-15 | Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud | Neuro-mesenchyme units control ilc2 and obesity via a brain-adipose circuit |
| CN116270429B (zh) * | 2023-02-17 | 2025-06-10 | 山东省药学科学院 | 一种鼻黏膜给药的抗抑郁制剂及其制备方法和应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008144919A1 (en) * | 2007-05-29 | 2008-12-04 | Angiochem, Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| WO2009039188A1 (en) * | 2007-09-17 | 2009-03-26 | Ludwig Institute For Cancer Research Ltd | Peptides and methods for the treatment of gliomas and other cancers |
| WO2009070597A2 (en) * | 2007-11-26 | 2009-06-04 | Armagen Technologies, Inc. | Fusion proteins for delivery of gdnf to the cns |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090016959A1 (en) * | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
| SI1859041T2 (sl) * | 2005-02-18 | 2015-04-30 | Angiochem Inc. | Polipeptidi aprotinina za prenos spojine prek krvno-moĹľganske pregrade |
| US8142781B2 (en) * | 2005-10-07 | 2012-03-27 | Armagen Technologies, Inc. | Fusion proteins for blood-brain barrier delivery |
-
2010
- 2010-06-11 AU AU2010258052A patent/AU2010258052A1/en not_active Abandoned
- 2010-06-11 WO PCT/CA2010/000889 patent/WO2010142035A1/en not_active Ceased
- 2010-06-11 MX MX2011013258A patent/MX2011013258A/es not_active Application Discontinuation
- 2010-06-11 CN CN2010800317596A patent/CN102459348A/zh active Pending
- 2010-06-11 CN CN201410030902.XA patent/CN103819564A/zh active Pending
- 2010-06-11 JP JP2012514307A patent/JP2012529272A/ja active Pending
- 2010-06-11 EP EP10785633A patent/EP2440581A4/en not_active Withdrawn
- 2010-06-11 US US13/377,480 patent/US20120196803A1/en not_active Abandoned
- 2010-06-11 CA CA2764777A patent/CA2764777A1/en not_active Abandoned
- 2010-06-11 BR BRPI1012971A patent/BRPI1012971A2/pt not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008144919A1 (en) * | 2007-05-29 | 2008-12-04 | Angiochem, Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| WO2009039188A1 (en) * | 2007-09-17 | 2009-03-26 | Ludwig Institute For Cancer Research Ltd | Peptides and methods for the treatment of gliomas and other cancers |
| WO2009070597A2 (en) * | 2007-11-26 | 2009-06-04 | Armagen Technologies, Inc. | Fusion proteins for delivery of gdnf to the cns |
Non-Patent Citations (1)
| Title |
|---|
| ULKAN KILIC等: "Intravenous TAT-GDNF Is Protective After Focal Cerebral Ischemia in Mice", 《STROCK》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107141354A (zh) * | 2017-05-05 | 2017-09-08 | 李斯文 | 一种融合蛋白及光敏剂复合物及其制备方法和应用 |
| CN114729324A (zh) * | 2019-07-24 | 2022-07-08 | 斯比根公司 | 永生化干细胞株的制备方法及其用途 |
| WO2025067354A1 (zh) * | 2023-09-28 | 2025-04-03 | 广州必贝特医药股份有限公司 | 抑制淀粉样前体蛋白(APP)基因表达的siRNA、药物及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010142035A1 (en) | 2010-12-16 |
| US20120196803A1 (en) | 2012-08-02 |
| MX2011013258A (es) | 2012-02-28 |
| JP2012529272A (ja) | 2012-11-22 |
| AU2010258052A1 (en) | 2012-01-12 |
| CN102459348A (zh) | 2012-05-16 |
| CA2764777A1 (en) | 2010-12-16 |
| BRPI1012971A2 (pt) | 2018-01-16 |
| EP2440581A1 (en) | 2012-04-18 |
| EP2440581A4 (en) | 2013-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103819564A (zh) | 用于将gdnf和bdnf递送至中枢神经系统的融合蛋白 | |
| EP2370471B1 (en) | Neurotensin conjugate and uses thereof | |
| US20250123275A1 (en) | Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use | |
| AU2009322044A1 (en) | Leptin and leptin analog conjugates and uses thereof | |
| WO2011153642A1 (en) | Leptin and leptin analog conjugates and fusion proteins and uses thereof | |
| AU2013273894A1 (en) | Targeted iduronidase compounds | |
| US20020156236A1 (en) | Binding sites for phosphotyrosine binding domains | |
| WO2020083905A1 (en) | Inhibitors of pick1 and uses thereof | |
| JPH05271291A (ja) | 機能性ポリペプチド | |
| HK1162541B (en) | Neurotensin conjugate and uses thereof | |
| HK1162541A (en) | Neurotensin conjugate and uses thereof | |
| WO1998017242A1 (en) | Unique peptides for targeting fibronectin-enriched surfaces and a method for their delivery in the treatment of metastatic cancer | |
| MXPA06002557A (es) | Compuestos que modulan el crecimiento neuronal y sus usos | |
| WO2014014816A2 (en) | Methods of treating glucose metabolism disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140528 |